{"id":106706,"name":"NEUROCRINE BIOSCIENCES, INC.","slug":"neurocrine-biosciences-inc","state":"CA","description":"Biotechnology company","totalSpending":1500000,"filings":25,"yearlySpending":[{"year":2018,"income":240000},{"year":2019,"income":240000},{"year":2020,"income":120000},{"year":2021,"income":180000},{"year":2022,"income":240000},{"year":2024,"income":180000},{"year":2025,"income":300000}],"firms":["BGR GOVERNMENT AFFAIRS"],"lobbyists":["DAVID BOYER","BRENT DEL MONTE","ROBB WALTON","JOHN STONE","MATT HOFFMANN","REMY MASON","DANIEL FARMER","ROBERT WOOD","JOEL BAILEY","RAGHAV AGGARWAL","MARVIN FIGUEROA"],"issues":["PHA"],"sampleDescriptions":["Advise client on legislative and administrative policy-making related to the biopharmaceutical industry generally, and client priorities specifically. Includes raising awareness among public officials about the importance of addressing disease areas of high unmet medical need where client is working to develop and market new medicines.","Advise client on legislative and administrative policy-making related to the biopharmaceutical industry generally, and client priorities specifically. Includes raising awareness among public officials about the importance of addressing disease areas of high unmet medical need where client is working to develop and market new medicines","Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally, and Neurocrine Biosciences, Inc. specifically.","Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally such as drug pricing and telehealth policy"],"years":[2018,2019,2020,2021,2022,2024,2025]}